This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase I trial presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics by researchers at The University of Texas MD Anderson Cancer Center.
The study evaluated MICVO in patients with recurrent or metastatic head and neck squamous cell carcinoma who had progressed after prior therapies, a setting where historical response rates are approximately 15%.
Among 33 efficacy-evaluable patients, MICVO achieved a confirmed overall response rate of 39%, including one complete response. Median progression-free survival was 6.7 months, and the one-year overall survival rate was 81%. Responses were observed regardless of HPV status or prior treatment history.
The data were presented by Principal Investigator Faye Johnson, M.D., Ph.D., professor of Head & Neck Medical Oncology.
"These results are encouraging because patients with recurrent or metastatic head and neck cancer have very limited treatment options once their disease progresses after initial therapy, and the treatments currently available are effective for only a small proportion of patients," Johnson said.
"This is a substantial unmet need, affecting approximately 20,000 patients each year in the U.S., and these findings suggest micvotabart pelidotin may offer a promising new option for this population."
MICVO works by binding to a specific target in the scaffolding of the tumor that surrounds the cancer cells known as extradomain-B of fibronectin, which allows MICVO to release a therapeutic payload directly to a tumor.
Source link







